Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Type 2 diabetes mellitus~2. HbA1c \>= 7.0%~3. Age \>= 70 years~4. Signed and dated written informed consent~Exclusion criteria:~1. Myocardial infarction, stroke or TIA within 3 months prior to informed consent~2. Impaired hepatic function~3. Treatment with glitazones, GLP-1 analogues, DPP-4 inhibitors or rapid acting or pre-mixed insulins~4. Treatment with anti-obesity drugs

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- linagliptin (Type: EXPERIMENTAL): patients receive linagliptin 5 mg tablets once daily
- placebo (Type: PLACEBO_COMPARATOR): patients receive placebo tablets matching linagliptin 5 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).